Ocugen, Inc.
Case Overview
43 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 06/10/2024 |
Status: | Status: Investigating |
Company Name: | Company Name: Ocugen, Inc. |
Case Number: | Case Number: 2:24cv01500 |
Class Period: | Class Period: 05/08/2020 - 04/01/2024 |
Ticker: | Ticker: OCGN |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of those who acquired Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) securities during the period of May 8, 2020 through April 1, 2024, inclusive (“the Class Period”). Investors have until June 10, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On April 1, 2024, Ocugen filed with the United States Securities and Exchange Commission ("SEC") a current report on its Form 8-K which reported that the Audit Committee of the Ocugen Board of Directors concluded that the Company's previously issued consolidated financial statements for each fiscal year beginning January 1, 2020 were materially misstated and should no longer be relied upon. Identified errors were found in each of the following financial statement line item captions: Collaborative arrangement revenue, Research and development expenses, Other income (expense), net and Accrued expenses and other current liabilities.
Also on April 1, 2024, the Company filed a notification of inability to timely file Form 10-K on Form 12b-25 due to additional time required for the Company to correct the errors described above and prepare restated financial statements. On this news, the price of Ocugen shares declined by $0.16 per share, or approximately 10.38%, to close at $1.38 per share on April 2, 2024.
On April 1, 2024, Ocugen filed with the United States Securities and Exchange Commission ("SEC") a current report on its Form 8-K which reported that the Audit Committee of the Ocugen Board of Directors concluded that the Company's previously issued consolidated financial statements for each fiscal year beginning January 1, 2020 were materially misstated and should no longer be relied upon. Identified errors were found in each of the following financial statement line item captions: Collaborative arrangement revenue, Research and development expenses, Other income (expense), net and Accrued expenses and other current liabilities.
Also on April 1, 2024, the Company filed a notification of inability to timely file Form 10-K on Form 12b-25 due to additional time required for the Company to correct the errors described above and prepare restated financial statements. On this news, the price of Ocugen shares declined by $0.16 per share, or approximately 10.38%, to close at $1.38 per share on April 2, 2024.